Company Announcement Transaction adds petosemtamab, a late-stage asset with two Breakthrough Therapy Designations, to Genmab’s portfolio ...
NEW YORK , Nov. 21, 2025 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for...
SAN DIEGO and UTRECHT, The Netherlands and CAMBRIDGE, Mass. , Nov. 17, 2025 /PRNewswire/ -- Merus N.V. (Nasdaq: MRUS) ("Merus"), an oncology company developing innovative, full-length multispecific...
Shareholders should contact the firm immediately as there may be limited time to enforce your rights.
Shareholders should contact the firm immediately as there may be limited time to enforce your rights.
NEW YORK , Nov. 4, 2025 /PRNewswire/ --
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti , LLC (“KSF”) are investigating the proposed sale of Merus N.V....
NEW YORK , Oct. 21, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches...
NEW YORK , Oct. 21, 2025 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars...
Canaccord Genuity analyst John Newman maintained a Hold rating on Merus today and set a price target of $97.00. The company’s shares closed yesterday at $94.83.Elevate Your Investing Strategy: Take advantage...